2021 Q4 RemedyOne Quarterly Pipeline Report

RemedyOne cuts through the complexity of modern pharmaceutical programs to uncover opportunities to grow, to flex agreements in your favor and to help you take decisive action on what matters.

Download our 2021 Q4  Quarterly Drug Pipeline Report

Our quarterly pipeline report provides insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful tool for your team to keep updated on the latest drugs to market and to plan pharmacy benefits.
 

Our report is broken into four sections to help your team:

  • Generic Launch
  • Specialty and Traditional
  • New-drug Indication
  • Comments & Insights Section

The Generic Launch section details which branded drugs will be released as first-time generics, their estimated date of release or loss of exclusivity, and the number of manufacturers competing for the generic alternatives. We also provide financial data that shows the 2020 sales for the brand drugs.

The information provided is for informational purposes only and should not be solely relied upon for decision-making purposes.

Facebook
Twitter
LinkedIn

Rebate and Formulary Management

RemedyOne cuts through the complexity of the pharmaceutical world by providing guidance and cost savings to PBMs, Employer Groups, Health Plans, and Third-Party Administrators.
Play Video

Rebate and Formulary Management

RemedyOne cuts through the complexity of the pharmaceutical world by providing guidance and cost savings to PBMs, Employer Groups, Health Plans, and Third-Party Administrators.
Play Video

Insights

Like what you’re seeing? Get more Insights sent to you.